<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02842320</url>
  </required_header>
  <id_info>
    <org_study_id>P/2015/244</org_study_id>
    <nct_id>NCT02842320</nct_id>
  </id_info>
  <brief_title>Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)</brief_title>
  <acronym>CAR-LMC</acronym>
  <official_title>Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The tyrosine kinase inhibitor therapy (iTKs) is the first-line treatment of chronic
      myelogenous leukemia (CML).

      Its effectiveness in controlling the progression of the disease is such that it is possible
      today to consider stopping treatment in patients with deep molecular response (&gt; RM4.0).

      Only in about 50% of cases, patients relapse. It has been shown in these patients that
      hematopoietic stem cells (HSCs) are persistant, quiescent and insensitive to iTKs. These
      cells are probably at the origin of relapse. It is therefore necessary to develop
      complementary therapies to cure the disease and consider discontinuation iTKs The development
      of anti-tumor immunotherapy approach using genetically modified T cells to express a chimeric
      antigen receptor (CAR) and specifically targeting CML CSH + could address this issue. The
      membrane expression of the IL-1-RAP protein could be an interesting target.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IL1RAP protein expression on the surface of cells detected by flow cytometry</measure>
    <time_frame>up to 2 years after inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Additional biological samples</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bone marrow sample and blood collected at J0 (screening visit), and at 3, 6, 12, 18 and 24 months and at each additional consultations (relapse ...)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biological samples</intervention_name>
    <description>bone marrow and blood</description>
    <arm_group_label>Additional biological samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients for whom there is a strong suspicion of CML diagnosed as part of routine
             activity.

          -  written informed consent

        Exclusion Criteria:

          -  patient with atypical CML

          -  patient with a non SMP CML

          -  patients previously treated with interferon

          -  patient enrolled in another study therapy or within the exclusion period thereof

          -  pregnant or breast-feeding women

          -  patient under guardianship, curator or under the protection of justice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe FERRAND, Dr</last_name>
    <email>christophe.ferrand@efs.sante.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabrice LAROSA, Dr</last_name>
    <email>flarosa@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Belfort</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marius Moldovan, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Marius Moldovan, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice LAROSA, Dr</last_name>
      <email>flarosa@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis CAILLOT, Dr</last_name>
      <email>denis.caillot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Denis CAILLOT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI de Haute-Saône</name>
      <address>
        <city>Vesoul</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyril FAURE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Cyril FAURE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

